Jason Zemansky
Stock Analyst at B of A Securities
(4.69)
# 117
Out of 4,817 analysts
34
Total ratings
69.57%
Success rate
29.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Neutral | $62 → $54 | $37.81 | +42.82% | 4 | Apr 15, 2025 | |
| INSM Insmed | Maintains: Buy | $92 → $96 | $71.16 | +34.91% | 9 | Mar 20, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $22 → $17 | $8.11 | +109.62% | 5 | Feb 19, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $6.30 | +360.32% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $12.89 | +140.50% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $0.93 | +168.90% | 5 | Jun 20, 2024 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $10 | $0.83 | +1,112.12% | 4 | May 12, 2023 | |
| ALLK Allakos | Maintains: Buy | $145 → $155 | $0.33 | +47,475.20% | 2 | Dec 13, 2021 |
Cytokinetics
Apr 15, 2025
Maintains: Neutral
Price Target: $62 → $54
Current: $37.81
Upside: +42.82%
Insmed
Mar 20, 2025
Maintains: Buy
Price Target: $92 → $96
Current: $71.16
Upside: +34.91%
Arcus Biosciences
Feb 19, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $8.11
Upside: +109.62%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $6.30
Upside: +360.32%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $12.89
Upside: +140.50%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $0.93
Upside: +168.90%
Werewolf Therapeutics
May 12, 2023
Maintains: Buy
Price Target: $9 → $10
Current: $0.83
Upside: +1,112.12%
Allakos
Dec 13, 2021
Maintains: Buy
Price Target: $145 → $155
Current: $0.33
Upside: +47,475.20%